FABP4 and myeloproliferative disorder: Similarly, the percentage of FABP4-positive BMAds was not significantly different among the three groups even though a trend towards reduction was observed in the neoplastic samples (CTR vs MET p = 0.0903; CTR vs MPN-MF p = 0.0638) (Figures 2, E–H, R).